Fluocinolone acetonide cream is another topical corticosteroid used by people with eczema, dermatitis and other skin conditions. There are no substitutes for these creams, and a prescription is necessary for proper care and safety. Like triamcinolone acetonide creams, flucoinconole acetonide creams provide moisturizing relief and inflammation treatment for the skin, and although these creams will relieve red, itchy symptoms, they will not cure them. In addition, the creams should only be used on patches of skin, not on large areas. The side effects of fluocinolone include bruising, discoloration, the appearance of spidery blood vessels or the thinning of skin. A doctor should be consulted if any of these side effects appear, and as there are no substitutes for these creams, a prescription is required for proper care and safety.
Formerly owned by ALTANA AG , the company (then named Altana Inc.) was bought by Nycomed in 2007, along with ALTANA AG's other pharmaceutical operations, and was renamed Nycomed US. In September 2011 Nycomed International was acquired by Japanese drugmaker Takeda Pharmaceutical for € billion ($14 billion); however, the autonomous Nycomed US business didn't fit into Takeda's global growth strategy and was excluded from the deal. Following Nycomed International's acquisition by Takeda, Nycomed US changed its name to Fougera Pharmaceuticals. The firm was owned by the same private investor group (including Nordic Capital, Credit Suisse , Collier International, and Avista Capital Partners) that previously owned Nycomed International; the investor group sold Fougera to Sandoz less than a year later.